FDA Enforcement Action On Drug Promotions Often Spurred By Competitors’ Complaints
This article was originally published in The Pink Sheet Daily
Executive Summary
Competitive complaints “point out so many instances where we may not be otherwise aware of activities going on,” CDER ad review division director Abrams says at DIA annual meeting. The agency receives over 200 complaints per year on prescription drug promotion.